在现实生活中使用新型抗聚集剂的临床结果

Iván J. Núñez Gil , Francisco Marín
{"title":"在现实生活中使用新型抗聚集剂的临床结果","authors":"Iván J. Núñez Gil ,&nbsp;Francisco Marín","doi":"10.1016/S1131-3587(19)30026-3","DOIUrl":null,"url":null,"abstract":"<div><p>The increasing amount of real-world data available on the use of double antiplatelet therapy with new antiplatelet agents, including data from Spanish centers (e.g. the EPICOR, ARIAM and ACHILLES studies), appear to confirm the findings of large pivotal trials. Generally, use of these agents results in substantial clinical benefits, including fewer ischemic events and lower mortality, but there is usually an associated increase risk of hemorrhage. The uptake of these new antiplatelet agents continues to grow relative to that of clopidogrel-based double antiplatelet therapy. In addition, prolonged use of dual antiplatelet therapy is common practice in the real world, with substantial variations between countries. Therapeutic outcomes depend to a large extent on the risk profiles of, and the balance between ischemic and hemorrhagic risk in, patients included in individual case series.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Resultados clínicos del uso de los nuevos antiagregantes en la vida real\",\"authors\":\"Iván J. Núñez Gil ,&nbsp;Francisco Marín\",\"doi\":\"10.1016/S1131-3587(19)30026-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The increasing amount of real-world data available on the use of double antiplatelet therapy with new antiplatelet agents, including data from Spanish centers (e.g. the EPICOR, ARIAM and ACHILLES studies), appear to confirm the findings of large pivotal trials. Generally, use of these agents results in substantial clinical benefits, including fewer ischemic events and lower mortality, but there is usually an associated increase risk of hemorrhage. The uptake of these new antiplatelet agents continues to grow relative to that of clopidogrel-based double antiplatelet therapy. In addition, prolonged use of dual antiplatelet therapy is common practice in the real world, with substantial variations between countries. Therapeutic outcomes depend to a large extent on the risk profiles of, and the balance between ischemic and hemorrhagic risk in, patients included in individual case series.</p></div>\",\"PeriodicalId\":34926,\"journal\":{\"name\":\"Revista Espanola de Cardiologia Suplementos\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola de Cardiologia Suplementos\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1131358719300263\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Cardiologia Suplementos","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1131358719300263","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

新的抗血小板药物联合双重抗血小板治疗的真实数据越来越多,包括来自西班牙中心的数据(如EPICOR、ARIAM和ACHILLES研究),似乎证实了大型关键试验的发现。一般来说,使用这些药物会带来实质性的临床益处,包括减少缺血事件和降低死亡率,但通常会增加出血的风险。与以氯吡格雷为基础的双重抗血小板治疗相比,这些新型抗血小板药物的应用继续增长。此外,长期使用双重抗血小板治疗在现实世界中是常见的做法,各国之间存在很大差异。治疗结果在很大程度上取决于个体病例系列中患者的风险概况以及缺血性和出血风险之间的平衡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Resultados clínicos del uso de los nuevos antiagregantes en la vida real

The increasing amount of real-world data available on the use of double antiplatelet therapy with new antiplatelet agents, including data from Spanish centers (e.g. the EPICOR, ARIAM and ACHILLES studies), appear to confirm the findings of large pivotal trials. Generally, use of these agents results in substantial clinical benefits, including fewer ischemic events and lower mortality, but there is usually an associated increase risk of hemorrhage. The uptake of these new antiplatelet agents continues to grow relative to that of clopidogrel-based double antiplatelet therapy. In addition, prolonged use of dual antiplatelet therapy is common practice in the real world, with substantial variations between countries. Therapeutic outcomes depend to a large extent on the risk profiles of, and the balance between ischemic and hemorrhagic risk in, patients included in individual case series.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista Espanola de Cardiologia Suplementos
Revista Espanola de Cardiologia Suplementos Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.20
自引率
0.00%
发文量
1
期刊介绍: Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.
期刊最新文献
Riesgo residual. Conclusiones Consideraciones clínicas y estrategias terapéuticas para reducir el riesgo residual Icosapento de etilo en la disminución del riesgo residual. Nuevas evidencias Recomendaciones actuales de las guías respecto al riesgo residual ¿Qué es el riesgo cardiovascular residual? Etiología, lípidos e inflamación
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1